Entera Bio Ltd. (ENTX) and OPKO Health, Inc. (OPK) recently announced positive topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin (OXM) analog developed by OPKO and Entera's proprietary N-Tab technology. The program is focused on developing the first oral dual agonist GLP-1/glucagon peptide as a potential oncedaily treatment for patients with obesity and metabolic and fibrotic disorders. OXM is a naturally occur ...